Cargando…

Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer

PURPOSE: The purpose of this study was to observe the clinical efficacy and toxicity of cisplatin in combination with gemcitabine or Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 200 patients with advanced NSCLC, which was c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ai, Dan, Guan, Yan, Liu, Xiu-Ju, Zhang, Chu-Feng, Wang, Peng, Liang, Hong-Lu, Guo, Qi-Sen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033500/ https://www.ncbi.nlm.nih.gov/pubmed/27695347 http://dx.doi.org/10.2147/OTT.S109683

Ejemplares similares

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma
por: Li, Xiao‐Min, et al.
Publicado: (2022)

Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity
por: Luo, Yang, et al.
Publicado: (2015)

First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
por: Li, Ying, et al.
Publicado: (2014)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
por: Hong, Shaodong, et al.
Publicado: (2021)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
por: Suzuki, Yuko, et al.
Publicado: (2018)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
por: Cappuzzo, F, et al.
Publicado: (2004)

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yang, Jiangping, et al.
Publicado: (2020)

Safety of adjuvant gemcitabine plus cisplatin chemotherapy in a patient with bilateral ureteral cancer undergoing hemodialysis
por: Goto, Yumiko, et al.
Publicado: (2021)

Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer
por: Miyake, Makito, et al.
Publicado: (2022)

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis
por: Schlick, Konstantin, et al.
Publicado: (2023)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
por: Yamamoto, Akinaru, et al.
Publicado: (2020)

A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy
por: Guo, Yupeng, et al.
Publicado: (2022)

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
por: Park, Keunchil, et al.
Publicado: (2017)

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
por: Paz-Ares, L., et al.
Publicado: (2016)

Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study
por: Ren, Xiang, et al.
Publicado: (2022)

Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens
por: Zheng, Li, et al.
Publicado: (2018)

Comparison Efficacy and Safety of Gemcitabine plus Cisplatin and 5-Fluorouracil plus Cisplatin for Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis and Systematic Review
por: Yan, Le, et al.
Publicado: (2022)

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
por: OZKAYA, SEVKET, et al.
Publicado: (2012)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
por: Kim, R D, et al.
Publicado: (2018)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
por: Zeng, Tian-mei, et al.
Publicado: (2023)

Editorial Comment to Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
por: Kandori, Shuya
Publicado: (2020)

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
por: Kim, Dong-Wan, et al.
Publicado: (2019)

Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
por: You, Min su, et al.
Publicado: (2019)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma
por: Li, Yin, et al.
Publicado: (2015)

Successful radical surgical resection of initially unresectable intrahepatic cholangiocarcinoma by downsizing chemotherapy with gemcitabine plus cisplatin: a case report
por: Takayanagi, Ryosuke, et al.
Publicado: (2017)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study
por: Cheng, Daoan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d7bf38ebvumjid086m958f5i84